Single dose of erdafitinib showed no dose changes needed for mild or moderate liver issues

People with liver problems often worry that their medicine needs special handling. This study looked at a single dose of erdafitinib in people with mild or moderate liver impairment compared to healthy people. The goal was to see if the drug moved through the body differently. It did not. The amount of drug in the blood stayed very similar across all groups. The time it took to reach peak levels was also the same. No new safety signals appeared. The drug was well tolerated by everyone who took it. No serious side effects occurred. No one had to stop taking the drug because of safety issues. This means doctors can prescribe this medicine without changing the dose for patients with these specific liver conditions. The results give peace of mind to patients and doctors alike. It confirms that the standard dose works safely for most people with these liver issues.